Traws Pharma, Inc. (NASDAQ:TRAW) Given Consensus Recommendation of “Reduce” by Brokerages

Traws Pharma, Inc. (NASDAQ:TRAW) has earned an average recommendation of “Reduce” from the five research firms that are presently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation and three have given a hold recommendation to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $1.00.

A number of equities analysts have issued reports on TRAW shares. Wall Street Zen upgraded Traws Pharma from a “strong sell” rating to a “sell” rating in a report on Saturday, June 13th. LADENBURG THALM/SH SH downgraded shares of Traws Pharma from a “buy” rating to a “neutral” rating in a research report on Monday, June 15th. Weiss Ratings lowered shares of Traws Pharma from a “sell (d)” rating to a “sell (e+)” rating in a research note on Friday, May 29th. Citigroup cut shares of Traws Pharma to a “neutral” rating in a report on Monday, June 15th. Finally, HC Wainwright reaffirmed a “negative” rating and issued a $1.00 price target on shares of Traws Pharma in a research note on Thursday, June 18th.

Insider Activity

In other news, major shareholder Orbimed Advisors Llc bought 597,729 shares of Traws Pharma stock in a transaction dated Thursday, April 16th. The stock was bought at an average cost of $1.67 per share, for a total transaction of $998,207.43. Following the purchase, the insider directly owned 1,203,250 shares in the company, valued at approximately $2,009,427.50. This represents a 98.71% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 7.57% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC grew its stake in Traws Pharma by 41.9% in the fourth quarter. Geode Capital Management LLC now owns 61,653 shares of the company’s stock valued at $70,000 after acquiring an additional 18,213 shares during the period. Adage Capital Partners GP L.L.C. raised its position in shares of Traws Pharma by 121.2% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 730,000 shares of the company’s stock worth $825,000 after purchasing an additional 400,000 shares during the period. Squadron Capital Management LLC acquired a new position in shares of Traws Pharma during the fourth quarter worth approximately $806,000. Ikarian Capital LLC lifted its holdings in shares of Traws Pharma by 2,280.0% in the 4th quarter. Ikarian Capital LLC now owns 678,142 shares of the company’s stock worth $766,000 after purchasing an additional 649,649 shares in the last quarter. Finally, Boothbay Fund Management LLC bought a new position in shares of Traws Pharma in the 4th quarter worth $220,000. 7.95% of the stock is owned by institutional investors and hedge funds.

Traws Pharma Stock Up 2.0%

TRAW stock opened at $0.68 on Friday. The firm has a market cap of $6.86 million, a price-to-earnings ratio of -0.40 and a beta of 1.51. The company’s fifty day simple moving average is $1.26 and its 200 day simple moving average is $1.56. Traws Pharma has a 12-month low of $0.64 and a 12-month high of $3.27.

Traws Pharma (NASDAQ:TRAW) last announced its earnings results on Friday, May 15th. The company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.92) by $0.39. Research analysts expect that Traws Pharma will post -1.43 earnings per share for the current year.

Traws Pharma Company Profile

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.